The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Factors Associated With Severe Late Toxicity After Concurrent Chemoradiation for Locally Advanced Head and Neck Cancer: An RTOG Analysis
Open accessAbstract
Purpose: Concurrent chemoradiotherapy (CCRT) for squamous cell carcinoma of the head and neck (SCCHN) increases both local tumor control and toxicity. This study evaluates clinical factors that are associated with and might predict severe late toxicity after CCRT. Methods: Patients were analyzed from a subset of three previously reported Radiation Therapy Oncology Group (RTOG) trials of CCRT for locally advanced SCCHN (RTOG 91-11, 97-03, and 99-14). Severe late toxicity was defined in this secondary analysis as chronic grade 3 to 4 pharyngeal/laryngeal toxicity (RTOG/European Organisation for the Research and Treatment of Cancer late toxicity scoring system) and/or requirement for a feeding tube ≥ 2 years after registration and/or potential treatment-related death (eg, pneumonia) within 3 years. Case-control analysis was performed, with a multivariable logistic regression model that included pretreatment and treatment potential factors. Results: A total of 230 patients were assessable for this analysis: 99 patients with severe late toxicities and 131 controls; thus, 43% of assessable patients had a severe late toxicity. On multivariable analysis, significant variables correlated with the development of severe late toxicity were older age (odds ratio 1.05 per year; P = .001); advanced T stage (odds ratio, 3.07; P = .0036); larynx/hypopharynx primary site (odds ratio, 4.17; P = .0041); and neck dissection after CRT (odds ratio, 2.39; P = .018). Conclusion: Severe late toxicity after CCRT is common. Older age, advanced T-stage, and larynx/hypopharynx primary site were strong independent risk factors. Neck dissection after CCRT was associated with an increased risk of these complications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Statistical Analysis of Failure Time Data.
Aitkin, M., Kalbfleisch, J. D., & Prentice, R. L. (1981) · Biometrics · doi:10.2307/2530581 · Cited by 9,877
A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk
Gray, R. J. (1988) · The Annals of Statistics · doi:10.1214/aos/1176350951 · Cited by 4,960
Concurrent Chemotherapy and Radiotherapy for Organ Preservation in Advanced Laryngeal Cancer
Forastiere, A. A., Goepfert, H., Maor, M., Pajak, T. F., Weber, R., Morrison, W., Glisson, B., Trotti, A., Ridge, J. A., Chao, C., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa031317 · Cited by 3,174
Self-citationPignon, J. (2000) · The Lancet · doi:10.1016/s0140-6736(00)90011-0 · Cited by 2,543
The Statistical Analysis of Failure Time Data
Klein, J. P. (1982) · Technometrics · doi:10.1080/00401706.1982.10487769 · Cited by 2,215
Trotti, A., Bellm, L. A., Epstein, J. B., Frame, D., Fuchs, H. J., Gwede, C. K., Komaroff, E., Nalysnyk, L., & Zilberberg, M. D. (2003) · Radiotherapy and Oncology · doi:10.1016/s0167-8140(02)00404-8 · Cited by 1,211
Self-citationBrizel, D. M., Albers, M. E., Fisher, S. R., Scher, R. L., Richtsmeier, W. J., Hars, V., George, S. L., Huang, A. T., & Prosnitz, L. R. (1998) · New England Journal of Medicine · doi:10.1056/nejm199806183382503 · Cited by 1,127
Calais, G., Alfonsi, M., Bardet, E., Sire, C., Germain, T., Bergerot, P., Rhein, B., Tortochaux, J., Oudinot, P., & Bertrand, P. (1999) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/91.24.2081 · Cited by 1,060
Denis, F., Garaud, P., Bardet, E., Alfonsi, M., Sire, C., Germain, T., Bergerot, P., Rhein, B., Tortochaux, J., & Calais, G. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.021 · Cited by 900
Pignon, J. P., Bourhis, J., Domenge, C., & Designe, L. (2001) · Cancer/Radiothérapie · doi:10.1016/s1278-3218(00)00073-1 · Cited by 700
Cited by
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Gillison, M. L., Trotti, A. M., Harris, J., Eisbruch, A., Harari, P. M., Adelstein, D. J., Jordan, R. C. K., Zhao, W., Sturgis, E. M., Burtness, B., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32779-x · Cited by 1,304
Self-citationTumor targeting via EPR: Strategies to enhance patient responses
Golombek, S. K., May, J.-N., Theek, B., Appold, L., Drude, N., Kiessling, F., & Lammers, T. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.07.007 · Cited by 1,262
“The response rate was found to be >70% without observation of severe toxicities [104], whereas severe side effects occurred when un-encapsulated chemotherapeutics were combined with radiotherapy [105,106].”
BackgroundMehanna, H., Robinson, M., Hartley, A., Kong, A., Foran, B., Fulton-Lieuw, T., Dalby, M., Mistry, P., Sen, M., O'Toole, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32752-1 · Cited by 1,041
Machiels, J.-P., René Leemans, C., Golusinski, W., Grau, C., Licitra, L., & Gregoire, V. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.07.011 · Cited by 916
Ang, K. K., Zhang, Q., Rosenthal, D. I., Nguyen-Tan, P. F., Sherman, E. J., Weber, R. S., Galvin, J. M., Bonner, J. A., Harris, J., El-Naggar, A. K., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.5633 · Cited by 838
Self-citationSroussi, H. Y., Epstein, J. B., Bensadoun, R., Saunders, D. P., Lalla, R. V., Migliorati, C. A., Heaivilin, N., & Zumsteg, Z. S. (2017) · Cancer Medicine · doi:10.1002/cam4.1221 · Cited by 797
The changing therapeutic landscape of head and neck cancer
Cramer, J. D., Burtness, B., Le, Q. T., & Ferris, R. L. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0227-z · Cited by 783
Radiation-induced fibrosis: mechanisms and implications for therapy
Straub, J. M., New, J., Hamilton, C. D., Lominska, C., Shnayder, Y., & Thomas, S. M. (2015) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-015-1974-6 · Cited by 677
Steuer, C. E., El‐Deiry, M., Parks, J. R., Higgins, K. A., & Saba, N. F. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21386 · Cited by 672
Recent Advances in Tumor Targeting via EPR Effect for Cancer Treatment
Subhan, M. A., Yalamarty, S. S. K., Filipczak, N., Parveen, F., & Torchilin, V. P. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11060571 · Cited by 623
“However, un-encapsulated nanodrugs, when combined with radiotherapy, may have severe side effects [149].”
BackgroundNguyen-Tan, P. F., Zhang, Q., Ang, K. K., Weber, R. S., Rosenthal, D. I., Soulieres, D., Kim, H., Silverman, C., Raben, A., Galloway, T. J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.3925 · Cited by 475
Self-citationPfister, D. G., Ang, K.-K., Brizel, D. M., Burtness, B. A., Cmelak, A. J., Colevas, A. D., Dunphy, F., Eisele, D. W., Gilbert, J., Gillison, M. L., et al. (2011) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2011.0053 · Cited by 413
Self-citationHuman papillomavirus as a driver of head and neck cancers
Sabatini, M. E., & Chiocca, S. (2020) · British Journal of Cancer · doi:10.1038/s41416-019-0602-7 · Cited by 387
Late dysphagia after radiotherapy‐based treatment of head and neck cancer
Hutcheson, K. A., Lewin, J. S., Barringer, D. A., Lisec, A., Gunn, G. B., Moore, M. W. S., & Holsinger, F. C. (2012) · Cancer · doi:10.1002/cncr.27631 · Cited by 383
Treatment of late sequelae after radiotherapy for head and neck cancer
Strojan, P., Hutcheson, K. A., Eisbruch, A., Beitler, J. J., Langendijk, J. A., Lee, A. W. M., Corry, J., Mendenhall, W. M., Smee, R., Rinaldo, A., et al. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.07.003 · Cited by 350
Current trends in initial management of laryngeal cancer: the declining use of open surgery
Silver, C. E., Beitler, J. J., Shaha, A. R., Rinaldo, A., & Ferlito, A. (2009) · European Archives of Oto-Rhino-Laryngology · doi:10.1007/s00405-009-1028-2 · Cited by 345
Transoral Robotic Surgery for Advanced Oropharyngeal Carcinoma
Weinstein, G. S., O’Malley, B. W., Cohen, M. A., & Quon, H. (2010) · Archives of Otolaryngology–Head & Neck Surgery · doi:10.1001/archoto.2010.191 · Cited by 320
Current trends in initial management of hypopharyngeal cancer: The declining use of open surgery
Takes, R. P., Strojan, P., Silver, C. E., Bradley, P. J., Haigentz, M., Wolf, G. T., Shaha, A. R., Hartl, D. M., Olofsson, J., Langendijk, J. A., et al. (2012) · Head & Neck · doi:10.1002/hed.21613 · Cited by 312
Head and Neck Cancers, Version 2.2014
Pfister, D. G., Spencer, S., Brizel, D. M., Burtness, B., Busse, P. M., Caudell, J. J., Cmelak, A. J., Colevas, A. D., Dunphy, F., Eisele, D. W., et al. (2014) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2014.0142 · Cited by 283
Self-citationOwadally, W., Hurt, C., Timmins, H., Parsons, E., Townsend, S., Patterson, J., Hutcheson, K., Powell, N., Beasley, M., Palaniappan, N., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1598-x · Cited by 277
Ojha, T., Pathak, V., Shi, Y., Hennink, W. E., Moonen, C. T. W., Storm, G., Kiessling, F., & Lammers, T. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.07.007 · Cited by 260
Janssens, G. O., Rademakers, S. E., Terhaard, C. H., Doornaert, P. A., Bijl, H. P., van den Ende, P., Chin, A., Marres, H. A., de Bree, R., van der Kogel, A. J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.9315 · Cited by 256
Kies, M. S., Holsinger, F. C., Lee, J. J., William, W. N., Glisson, B. S., Lin, H. Y., Lewin, J. S., Ginsberg, L. E., Gillaspy, K. A., Massarelli, E., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.0425 · Cited by 253
Self-citation
Metadata
- Authors
- Machtay, M., Moughan, J., Trotti, A., Garden, A. S., Weber, R. S., Cooper, J. S., Forastiere, A., & Ang, K. K.
- Venue
- Journal of Clinical Oncology
- Published
- 2008-07-20
- Volume
- 26
- Issue
- 21
- Pages
- 3582-3589
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2111442242
- Cited by
- 1,371
- References
- 26
- FWCI
- 47.65
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.